Institutional members access full text with Ovid®

Share this article on:

TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY WITH PHOTODYNAMIC THERAPY

Spaide, Richard F. MD*; Donsoff, Irene BA*; Lam, Deborah L. BA; Yannuzzi, Lawrence A. MD*; Jampol, Lee M. MD; Slakter, Jason MD*; Sorenson, John MD*; Freund, K. Bailey MD*

doi: 10.1097/IAE.0b013e31823f9b97
Reprint Article

Purpose: To study the effects of photodynamic therapy using verteporfin in the treatment of patients with subfoveal polypoidal choroidal vasculopathy (PCV).

Methods: A retrospective chart review of 16 consecutive patients with subfoveal PCV treated with photodynamic therapy using verteporfin was performed.

Results: The mean age of the patients involved was 70.5 years. The mean follow-up time was 12 months. The visual acuity improved in 9 (56.3 %), remained the same in 5 (31.3 %), and decreased in 2 (12.5 %). The mean change in visual acuity was an improvement of 2.38 lines, a difference that was highly significant (P = 0.004). The change in visual acuity was negatively correlated with increasing age. The final visual acuity was positively correlated with initial acuity and negatively correlated with age. These results were confirmed by multiple linear regression. No patient had any lasting complication from the treatment.

Conclusions: Subfoveal PCV has no proven method of treatment. Although the follow-up time and the number of patients in this pilot study were limited, the encouraging results and lack of complications suggest that further study is indicated.

*LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, and the Vitreous—Retina—Macula Consultants of New York, New York

Northwestern University Medical School, Chicago, Illinois.

Reprint requests: Richard F. Spaide, MD, Vitreous-Retina-Mac ula Consultants of New York, 519 East 72nd Street, Suite 203, New York, NY 10021; e-mail: VRMNY@aol.com

Supported by The Macula Foundation, Inc. and by an unrestricted grant from Research to Prevent Blindness, Inc., New York, NY (Northwestern University).

Drs. Jampol and Slakter are consultants for Novartis Ophthal-mics, Duluth, Georgia; otherwise, the other authors have no financial interests.

© The Ophthalmic Communications Society, Inc.